Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, which ...

However, things aren't all that rosy. In the last five years, Amgen's earnings per share has shrunk at approximately 9.7% per annum. If earnings continue declining, the company may have to make ...